Fluidigm BioMark HD and Juno integrated system

 描述(由申请人提供) 快速发展的基因组学技术推动了显着的研究突破，现在开始解释许多人类疾病以及自然变异的分子基础。俄亥俄州立大学综合癌症中心的基因组学共享资源(GSR)一直与这些不断发展的方法保持同步，为广泛的研究人员社区提供补充和尖端的基因组学服务。这些服务涉及基于测序、杂交和/或聚合酶链式反应(PCR)的方法。GSR工作人员帮助研究人员设计基因组实验并生成高质量的基因组数据，以支持他们的基础和临床研究项目。这个核心实验室主要支持俄亥俄州立大学的癌症研究，但也经常为俄亥俄州立大学和其他机构的其他研究领域提供服务。在这份S10共享仪器资助计划提案中，GSR建议收购一个灵活、高度可扩展的集成微流控系统，该系统使用各种形式的聚合酶链式反应(包括定量聚合酶链式反应、终点分析和数字聚合酶链式反应)促进定制和/或高通量分析。这个名为Fluidigm Juno Loader和BioMark HD的集成系统将允许GSR执行基于PCR的分析，以进行基因分型、定量转录表达水平(包括microRNA和替代RNA剪接)、基因组DNA拷贝数变化，甚至寡核苷酸标记的蛋白质。所要求的系统的一个特别的优点是它的高度可伸缩性，因此用于小型试验项目的相同的仪器和实验条件可以以直接和简单的方式扩大到数百个分析和数千个样本(甚至更多)。这一集成的Fluidigm系统将允许对包括下一代测序(NGS)在内的其他基因组学平台产生的数据进行快速和经济的验证。它加入GSR将支持和加强NIH资助的正在进行的研究项目。这很可能导致对人类疾病的新认识，从而为诊断、治疗和预防疾病以及改善人类健康创造新的机会。

 DESCRIPTION (provided by applicant) Rapidly evolving genomics technologies have driven remarkable research breakthroughs which are now beginning to explain the molecular basis for many human diseases as well as natural variation. The Genomics Shared Resource (GSR) of the Ohio State University Comprehensive Cancer Center has remained abreast of these evolving methods by providing complementary and cutting-edge genomics services to a broad community of investigators. These services involve sequencing, hybridization and/or polymerase chain reaction (PCR)-based methods. GSR staff members help investigators to design genomics experiments and generate high quality genomics data to support their basic and clinical research projects. This core laboratory primarily supports cancer research at Ohio State, but also routinely serves other research areas at Ohio State and at other institutions. In this S10 Shared Instrumentation Grant Program proposal, the GSR proposes to acquire a flexible, highly scalable, integrated microfluidics system that facilitates custom and/or high-throughput assays using various forms of PCR including quantitative PCR, end-point assays and digital PCR. This integrated system, called the Fluidigm Juno loader and BioMark HD, will allow the GSR to perform PCR-based assays for genotyping, quantitation of transcript expression levels including microRNAs and alternative RNA splicing, genomic DNA copy number changes, and even oligonucleotide-tagged proteins. A particular advantage of the requested system is that it is highly scalable, so the same instrument and experimental conditions for small pilot projects can be scaled up in a straightforward and simple way to hundreds of assays and many thousands of samples (or even more). This integrated Fluidigm system will allow for rapid and economical validation of data generated by other genomics platforms including next generation sequencing (NGS). Its addition to the GSR will support and enhance ongoing NIH- funded research projects. This is very likely to result in new insights into human diseases and thereby create new opportunities to diagnose, treat and prevent diseases and to improve human health.